Castrate-resistant Prostate Cancer Market

Report Highlights

The report broadly covers different treatment types of castrate-resistant prostate cancer based on their drug delivery method. Furthermore, the scope of the report also covers the impact of COVID-19 and drivers and challenges for castrate-resistant prostate cancer market. The report covers the market value for the historic year 2019, followed by the base year 2020, estimated year 2021 and forecast period from 2020 to 2026 for each treatment type, drug delivery method, end-user, and regional markets, and the estimated values are derived from the manufacturers’ total revenues.

The report also includes a discussion of the major players across each of the regional castrate-resistant prostate cancer markets; it explains the major market drivers of the global castrate-resistant prostate cancer industry, current trends within the industry, major applications, and the regional dynamics of the global castrate-resistant prostate cancer market.

The report concludes with a special focus on the vendor landscape, which includes detailed profiles of the major vendors in the global castrate-resistant prostate cancer market.

Report Includes

• 35 tables and 43 figures
• An up-to-date analysis of the Global Castrate-resistant Prostate Cancer Market.
• Analyses of the global market trends, with data from 2019, 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026.
• Estimation of market size and revenue forecast for Global Castrate-resistant Prostate Cancer Market, and corresponding market share analysis by treatment type, drug delivery method, end-user, and region.
• Highlights of emerging technology trends, gaps and opportunities in the market estimating current and future demand for Castrate-resistant Prostate Cancer, identification of the companies that are best positioned to meet this demand.
• In-depth information (facts and figures) concerning market drivers, restraints and other forces affecting the progress of this market.
• Identification of promising new products and therapies still in the development and testing stages, and their probability of successful commercial launch within the next five years
• Impact of COVID-19 on the Castrate-resistant Prostate Cancer Market as compared to overall global economy.
• Insight into the growth development strategies of major Castrate-resistant Prostate Cancer manufacturers and their key competitive landscape
• Descriptive company profiles of the leading market participants, including Sanofi S.A., Pfizer Inc., Johnson & Johnson, Bayer AG, AstraZeneca plc, Dendreon Corporation, Clovis Oncology, Inc., and others.

Summary

Castration-Resistant Prostate Cancer (CRPC) commonly known as Hormone Refractory Prostate Cancer (CRPC), is a kind of prostate cancer which typically persists even after administering androgen deprivation therapy (ADT). The global CRPC market is primed to grow at a significant rate, owing to elevated unmet clinical need, growing prevalence rates, reduced survival benefits, and fast and better emerging treatment alterations.

The growth of the market would revolve around the innovative breakthrough treatments responsible for securing survival benefits. This would help in the penetration of the novel drugs in the market. There are mainly four types of treatment type for this type of cancer which includes, chemotherapy, hormonal therapy, radiation therapy, and immunotherapy.